Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy
- 1 November 2017
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 2 (11), 1217-1225
- https://doi.org/10.1001/jamacardio.2017.3451
Abstract
Since 2015, 2 PCSK9 inhibitors (PCSK9i), alirocumab and evolocumab, have been approved for adults with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite maximally tolerated statin therapy and those with familial hypercholesterolemia.1,2 The retail cost for these PCSK9i can be as much as $14 000 per year, leading health insurers and pharmacy benefit managers (PBMs) to implement utilization management processes including prior authorization and patient therapy copays. To date, limited empirical information is available on how these preauthorization processes and copays jointly are associated with access to PCSK9i in community practice.Keywords
This publication has 6 references indexed in Scilit:
- Access to Nonstatin Lipid-Lowering Therapies in Patients at High Risk of Atherosclerotic Cardiovascular DiseaseCirculation, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseThe New England Journal of Medicine, 2017
- Cost-effectiveness of PCSK9 Inhibitor Therapy.JAMA, 2016
- Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular DiseaseJAMA, 2016
- Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United StatesClinical Cardiology, 2016
- What Does It Cost Physician Practices To Interact With Health Insurance Plans?Health Affairs, 2009